ONCOLOGY Vol 40, Issue 7

ALK rearrangements are uncommon but actionable oncogenic drivers in non–small cell lung cancer.

Although shortages periodically capture national attention when widely used agents such as cisplatin or carboplatin become scarce, the problem extends well beyond any single drug.

In part 1 of a 2-part interview, Frank McCormick, PhD, discusses the technical hurdles that made KRAS resistant to drug development, the NCI's RAS Initiative, and the RASolute 302 data.